Theorem Clinical Research Distributes Clinical Trial Advice
News Feb 28, 2013
Theorem Clinical Research has released two site-level reference booklets for clinical research sites that explain and condense critical International Conference on Harmonisation guidelines related to Good Clinical Practice for the conduct of trials.
Authored by Judith Köhnen and Lee Spurgin, PhD, “Little Advisor ICH GCP for Investigational Product Trials” explains key concepts of the ICH GCP requirements. Their second book, “Little Advisor ICH GCP for In Vitro Diagnostic Trials,” provides guidance on regulations specific to trials involving in vitro diagnostic devices. Both are available for purchase online.
Spurgin, senior vice president for medical device and diagnostic development, and Köhnen, senior project director for medical device and development, have years of experience with the conduct of clinical trials. Both manuals cover topics such as qualifications, regulatory authorities, ethics committees, the informed consent process, safety reporting and more. The information, presented in an easy-to-read format, highlights and explains critical information and provides practical advice.
“We developed these booklets to help investigators better understand the guidelines that govern clinical trials,” said Spurgin. “The guidelines themselves are lengthy and sometimes confusing. These manuals are an accessible resource for clinical research sites.”
A third booklet, previously released by Theorem, has been popularly received by sites seeking to understand the International Organization for Standardization’s requirements for medical device trials. “Little Advisor ISO 14155:2011 for Medical Device Trials” is also available online.
All three booklets provide full citations back to the original ISO or ICH GCP documents for those who need more detail. And, all the topics in the original document are included in the respective booklets.
Theorem Clinical Research’s reputation comes from years of focused experience in managing complex studies. By bringing together teams of clinical, regulatory and study management experts, Theorem provides innovative development programs across the entire spectrum. The company has the development and regulatory expertise to execute successful trials across all risk classifications and approval pathways globally. Theorem’s regulatory and health economics experts also develop adjunctive reimbursement and safety surveillance programs and provide ongoing marketing support.
Breath Test Could Simplify Drug and Disease TestingNews
Testing for drug use and disease in humans could soon be much simpler, thanks to new Swedish research.Scientists have demonstrated how collecting and analysing externally-produced compounds in the lining fluid of the airways allows for non-invasive testing and monitoring.The researchers used liquid chromatography-mass spectrometry to analyse the collected samples, as well as investigating the impact of different breathing patterns.READ MORE
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE